Pfizer, one of the leading pharmaceutical companies responsible for developing a COVID-19 vaccine, has once again found itself in hot water. The U.K. Prescription Medicines Code of Practice Authority (PMCPA) recently charged Pfizer administrative costs of £34,800 for breaching the code of practice. This is not the first time Pfizer has faced reprimand for its promotional activities surrounding the COVID-19 vaccine.
The specific incident that led to this latest fine involved a tweet shared by Dr. Berkeley Phillips, the Medical Director of Pfizer U.K. The tweet stated that Pfizer's vaccine candidate was 95% effective in preventing COVID-19 and 94% effective in people over 65 years old. It also mentioned that the company would be filing all of its data with health authorities soon. While this may seem like a harmless announcement, it violated Clause 3.1 of the code, which prohibits the promotion of a medicine prior to the grant of its marketing authorization.
The PMCPA panel noted that the tweet clearly referred to the outcome of Pfizer and BioNTech's vaccine being developed to protect against COVID-19. As a result, Pfizer was charged the administrative costs mentioned above. However, when we consider Pfizer's revenues, which jumped to $81.3 billion in 2021, the fine equates to a mere 0.00005% of their total revenue for that year. In fact, Pfizer earned approximately $154,680 per minute in 2021, so the fine amounts to roughly 17 seconds of their revenues. This raises questions about the effectiveness of such fines in deterring pharmaceutical companies from engaging in promotional activities that may be considered illegal or unethical.
This incident is not an isolated one for Pfizer. The company has already faced reprimand six times for its promotion of the COVID-19 vaccine. In November 2022, Pfizer's Chief Executive, Dr. Albert Bourla, was found guilty of misleading U.K. parents over the safety of the vaccine for children. Bourla had stated that annual COVID-19 vaccinations would likely be necessary for many years to come to maintain a high level of protection. He also advocated for immunizing children in the U.K. and Europe, citing the impact of COVID-19 on schools and the potential for severe symptoms in children.
Despite these violations and controversies, Dr. Albert Bourla has seen significant financial success. He was named CEO of the Year by CNN Business in 2021 and has an estimated net worth of at least $35.6 million. He owns a substantial amount of Pfizer stock and has sold significant amounts of stock over the past decade. This raises concerns about potential conflicts of interest and whether financial gains are prioritized over ethical practices.
Dr. Berkeley Phillips, who shared the controversial tweet, claimed that it was accidental and unintentional. However, many argue that at this level, everything is fine-tuned to promote the stock price and further the pharmaceutical agenda. The promotion of an unlicensed medicine or unauthorized indication is a criminal offense, punishable by fines or imprisonment for up to two years. It is time for pharmaceutical companies to face more significant penalties for breaches of the code rather than mere financial inconveniences.
The video below features Dr. Carl Heneghan, the Oxford Professor of Evidence Based Medicine, and Dr. Tom Jefferson, an epidemiologist based in Rome who works with Dr. Heneghan on the Cochrane Collaboration. They discuss the issue of Pfizer's promotional activities on social media and raise important questions about accountability and transparency within the pharmaceutical industry.
In conclusion, Pfizer's recent fine for breaching the code of practice highlights ongoing concerns about their promotional activities surrounding the COVID-19 vaccine. While the fine may seem significant at first glance, it is merely a drop in the bucket compared to Pfizer's revenues. The repeated violations and controversies involving Pfizer's executives raise questions about the prioritization of financial gains over ethical practices.
